8-K current report · filed Aug 6, 2026

LifeStance Health Group, Inc. (LFST) 8-K Current Report: August 6, 2026

Item 2.02Item 7.01Item 8.01Item EX-99.1Item EX-99.2LFST overview

Short answer

LifeStance Health Group, Inc. (LFST) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q2 2026 results announcement for quarter ended June 30, 2026.

LifeStance Health Group, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results announcement for quarter ended June 30, 2026
  • Press release issued August 6, 2026, with financial results in Exhibit 99.1

Item 7.01 · Regulation FD Disclosure

  • Exhibit 99.2 contains supplemental LifeStance Health Group information for investor review
  • Presentation details may provide additional operating or financial context beyond the 8-K summary

Item 8.01 · Other Events

  • New $100 million share repurchase authorization approved August 5, 2026
  • Program replaces prior $100 million authorization from February 24, 2026
  • Repurchases may support per-share metrics by reducing outstanding shares
  • No obligation or fixed timetable to deploy the authorization
  • Execution depends on share price, corporate needs, investment opportunities, and market conditions

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $435.4M, up 26%, with visits up 19% to 2.6M and clinicians up 11% to 8,542
  • Net income $23.6M versus $3.8M loss; Adjusted EBITDA $66.0M, up 94%, with margin reaching 15.2%
  • Operating cash flow $99.9M and free cash flow $87.9M, supporting continued investment and capital returns
  • FY 2026 guidance raised to $1.685B-$1.725B revenue and $215M-$235M Adjusted EBITDA
  • New $100M repurchase authorization replaces the prior $100M program; $97.625M repurchased during the first six months of 2026

Item EX-99.2 · Exhibit EX-99.2

  • Q2 revenue $435.4M, up 26% YoY, with visits up 19% to 2.6M and clinicians up 11% to 8,542
  • Adjusted EBITDA $66.0M, margin 15.2%, versus 9.8% in Q2 2025, signaling significant operating leverage
  • Center Margin $153.0M, margin 35.2%, up from 31.4% a year earlier
  • FY2026 guidance raised: revenue $1,685M-$1,725M and Adjusted EBITDA $215M-$235M
  • Cash $225.9M versus $259M net long-term debt, with $97.6M of share repurchases and $9.0M spent on acquisitions year-to-date

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other LifeStance Health Group, Inc. 8-K filings

Get the next LFST 8-K as it lands

Follow LFST for push alerts, or ask the research agent what this filing means.